布地奈德雾化吸入治疗尘肺病合并感染的临床观察及护理体会

Treatment of infection of pneumoconiosis patients with inhalation of budesonide aerosol

[目的]观察布地奈德雾化吸入治疗对尘肺病合并感染患者的临床效果。[方法]选取2015年1月—2016年1月期间入院治疗的尘肺病合并感染患者60例,将其随机分为对照组(n=30)和观察组(n=30)。对照组患者采用常规治疗,如吸氧、解痉、平喘及对症治疗。观察组患者除上述常规治疗外,加用布地奈德雾化吸入,每日两次,每次2 mg,连续用10 d,并对两组患者治疗后的临床效果进行比较。[结果]治疗后第10天,观察组患者疗效优于对照组,差异有统计学意义(P<0.05);观察组总有效率为96.7%,高于对照组的73.3%。两组患者治疗后的肺功能较治疗前均有所改善,且观察组FEV_1、FEV_1/FVC均高于对照组,差异有统计学意义(P<0.05)。[结论]布地奈德雾化吸入治疗尘肺病合并感染的临床效果较好,值得在临床上进一步推广和应用。

[Objective] To observe the clinical effect of budesonide aerosol in the treatment of infection of pneumoconiosis patients. [Methods] Totally 60 hospitalized pneumoeoniosis patients with infection from January 2014 to January 2015 were studied. They were randomly divided into 2 groups, namely the routine treatment group （n = 30） and the specific treatment group （n = 30）. Patients in the specific treatment group received inhalation of 2 mg budesonide aerosol twice a day for ten days, while the other treatment was the same as that in the control group, such as anti-inflammation, relieving asthma and oxygen therapy. The clinical therapeutic effects of these two groups of patients after treatment were compared. [Results] On the 10th day after treatment, the curative effect of the specific treatment group was better than that of the routine treatment group （P 〈 0.05）. The total effective rate was 96.7% in the specific treatment group and 73.3% in the routine treatment group. The patients＇ lung function in both groups was improved, but the FE1 and FEVt / FVC of patients in the specific treatment group showed much better （P 〈 0.05）. [Conclusion] The clinical effect of budesonide aerosol in the treatment of complicated infection of pneumoeoniosis patients was positive.